Investors
Personalized vaccines are possible. Access is the problem.
01
The problem
Cost
Bespoke workflows are expensive to run per patient.
Turnaround
Many sequential handoffs extend timelines.
Access
Few clinics can reach the full network.
02
Why now
Sequencing
Falling costs make tumour/normal profiling practical.
Computation
Advances in computational biology improve prioritization.
RNA/LNP
Capabilities are increasingly accessible.
03
The product
Neoantigen Retriever: computational pipelines for patient-specific neoantigen discovery and prioritization, coordinated with clinics, sequencing, wet-lab and RNA/LNP partners.
04
Why us
Execution
An open-source prototype with a public walkthrough.
Recognition
Health & Sciences Prize in Google’s Gemma 4 Good Challenge.
Team
Company execution, computational genomics and cancer research.
05
Market opportunity
Our initial focus is veterinary oncology clinics evaluating patient-specific vaccine workflows. We’re developing a clinic-led model, with sequencing, validation and manufacturing coordinated around each case.
We evaluate the opportunity through partner-clinic reach, suitable case volume, workflow uptake and fully loaded per-case economics.
06
Competitive landscape
Our focus is the complete clinic-to-vaccine workflow. We assess alternatives across:
07
Business model hypotheses
Per-case workflow
Clinics access coordinated analysis per patient.
Research partnerships
Collaborative studies with labs and institutions.
Platform licensing
Ecosystem partners access the pipeline.
08
Evidence & milestones
- Completed
2026
Working prototype
The original Project Rosie computational pipeline and demo.
- Completed
August 24, 2026
Health & Sciences Prize
Google’s Gemma 4 Good Challenge announcement.
- In progress
October 2026
Pipeline & clinical planning
Neoantigen Retriever development and clinic-connected study planning.
- Proposed
Next milestone
Wet-Lab Validation
Test prioritized targets with an immunology lab or CRO.
- Proposed
Conditional next stage
Clinical evaluation
Progress only with supporting evidence and an authorized protocol.
09
Capital priorities
Benchmarking
Rigorous in-silico evaluation.
Validation
First in-vitro experiments with partner labs.
Network
Formalizing clinical and manufacturing partnerships.
Our mission
Understand life from first principles.
Life is built from biological primitives and rules that we have only begun to understand. Our goal is to map them, model them, and eventually learn to program them.
We believe that understanding life from first principles can make disease tractable, extend healthy lifespan, and turn biological limits into engineering problems.
Where we begin
We’re starting with personalized cancer vaccines. We connect tumour sequencing, computational target selection, experimental validation, and mRNA delivery.
Start a conversation
Let’s talk about what comes next.
Tell us about your clinic or laboratory, your area of expertise and the collaboration you have in mind.
Email the team shashank.padala24@gmail.com